Columvi (glofitamab-gxbm) / Roche, Biogen - LARVOL DELTA

Hematotoxicity and immune deficits with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma (ASH 2025) - "Among NHL cohorts, the BsAb distribution was: 7 glofitamab, 6 mosunetuzumab, 5 epcoritamab, and 4 odronextamab. Among MM cohorts, 6 received teclistamab, 3 talquetamab, 1 teclistamab and talquetamab, 2 elranatamab, 2 linvoseltamab and 1 etentamig (ABBV-383)... Cytopenias affect a substantial proportion of patients treated with BsAbs, particularly in MM and in NHL with combination regimes. These findings support the need for systematic hematologic monitoring, IG surveillance and tailored pre-emptive strategies to mitigate infection risk.This study represents the first and most comprehensive meta-analysis of hematotoxicity and immune deficits with BsAbs, establishing a benchmark across clinical settings."

Retrospective data • Review • Hematological Malignancies • Infectious Disease • Lymphoma • Multiple Myeloma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia

Cardiovascular adverse events associated with bispecific antibodies in Relapsed/Refractory hematologic malignancies: A comprehensive systematic review and meta-analysis (ASH 2025) - "The study included seven bispecific antibodies (BsAbs) : blinatumomab , mosunetuzumab , elranatamab , epcoritamab , glofitamab , talquetamab , and teclistamab . While bispecific antibodies (BsAbs) show promising results in managing R/R hematologic malignancies, their use can lead to significant cardiac adverse effects, including tachycardia, arrhythmias, and hypotension. To mitigate these risks, a multidisciplinary approach—incorporating vigilant cardiac monitoring, preventive strategies, and prompt intervention—is essential for optimizing patient care and treatment success. Risk of Bias was relatively low."

Adverse events • Retrospective data • Review • Atrial Fibrillation • B Cell Lymphoma • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Hypertension • Hypotension • Lymphoma • Myocardial Infarction • Non-Hodgkin’s Lymphoma • Oncology

Incidence of second primary malignancies (SPMs) following bispecific antibody (BsAb) therapy for lymphoid malignancies: A descriptive analysis of clinical trials (ASH 2025) - "Included agents were blinatumomab (CD19×CD3), glofitamab, mosunetuzumab, epcoritamab, and odronextamab (all CD20×CD3), as well as elranatamab, teclistamab, and linvoseltamab (BCMA×CD3), and talquetamab (GPRC5DxCD3). Notably, some reported cases may represent disease progression rather than true SPMs. However, limited follow-up duration across trials warrants continued long-term surveillance, particularly as agents move to frontline settings where longer survival may reveal delayed malignancies."

Clinical • Acute Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lung Cancer • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • CD20

Comparative analysis of fatal serious adverse events associated with FDA-approved bispecific antibodies in hematologic malignancies (ASH 2025) - " Using the FDA Adverse Events Reporting System (FAERS) public dashboard case-listing feature up to Q2 2025, individual reports listings with death as an outcome were extracted for all FDA-approved BsAbs/BiTEs: blinatumomab, glofitamab, epcoritamab, teclistamab, elranatamab, and talquetamab. The FAERS-based analysis aligns with literature on BsAb/BiTEs toxicities: CRS and infections are consistently reported fatal SAEs, with ICANS more notable in BCMA-targeting agents. Notably, our study also reveals underappreciated signals: cardiovascular fatal events, rare neurological syndromes beyond ICANS, and opportunistic infections—which are not prominently featured in the literature but appear in real-world fatal outcomes. These findings highlight both expected and emerging fatal toxicity patterns across FDA-approved BiTEs/BiAbs."

Adverse events • Serious adverse event • Acute Lymphocytic Leukemia • CNS Disorders • Hematological Malignancies • Hypotension • Infectious Disease • Leukemia • Oncology • Pneumonia • Respiratory Diseases • Septic Shock

Comparative safety profiles of bispecific T-cell engagers and CAR-T therapies: Real-world insights from the FDA adverse event reporting system database (ASH 2025) - "BiTEs demonstrated a significantly higher disproportionality signal for neutropenia compared to CAR-T therapies (PRR=1.74, ROR=1.93, 95% CI [1.89, 1.98], p<0.001), with Glofitamab showing the highest reporting rate (42.2%) among BiTEs...Tisagenlecleucel had the highest hepatotoxicity rate (4.1%) among CAR-T agents...Axicabtagene ciloleucel had the highest venous thrombosis rate (42.6%) among CAR-T agents...Brexucabtagene autoleucel had the highest rate of arterial thrombosis (0.78%) among CAR-T agents. This real-world analysis reinforces the well-characterized neurotoxicity associated with CAR-T therapies, while highlighting the higher rate of neutropenia with BiTEs. These distinct toxicity profiles emphasize the importance of individualized treatment selection, considering patient comorbidities, toxicity tolerance, logistical factors, and the clinical context, which includes the potential for better disease control with specific therapies."

Adverse events • Clinical • Real-world • Real-world evidence • Acute Kidney Injury • Cardiovascular • Hematological Malignancies • Hepatology • Nephrology • Neutropenia • Renal Disease • Thrombosis • ROR1

Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort (ASH 2025) - "In this real-world cohort, rates of CRS were comparable, whereas ICANS incidence was slightly higher compared to pivotal trials, possibly due to broader patient eligibility, including older individuals and those with comorbidities or CNS involvement. Elevated baseline CRP predicted higher CRS severity, underscoring systemic inflammation as a driver of CRS. ICANS appeared slightly more common and were significantly associated with preexisting CNS involvement and baseline anemia, indicating vulnerability related to neurologic reserve or marrow function."

Clinical • IO biomarker • Real-world • Real-world evidence • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Diabetic Nephropathy • Heart Failure • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Metabolic Disorders • Neutropenia • Non-Hodgkin’s Lymphoma • Renal Disease • CD20 • CRP

Effectiveness and safety of bispecific antibodies in relapsed/refractory diffuse large B-cell lymphoma (DLBCL): A systematic review and meta-analysis (ASH 2025) - " Twelve eligible studies involving 744 patients were included, primarily evaluating glofitamab (6 studies), epcoritamab (2), mosunetuzumab (2), and odronextamab (2). Bispecific antibodies offer a promising therapeutic approach for relapsed/refractory DLBCL, particularly in heavily pretreated or CAR-T-ineligible patients. These findings support their expanding role in clinical practice and highlight the need for further real-world evidence. Multi-national randomized controlled trials with longer follow-up are needed to establish durability and optimize treatment sequencing."

Retrospective data • Review • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma

Optim.AI™ 2.0: Functional precision platform for identifying effective immunotherapy combinations in DLBCL (ASH 2025) - "PBMCs were added to tumor cells at a fixed effector-to-target ratio, and Optim.AI 2.0 combinatorial drug sensitivity testing plates were applied to the co-culture system, with up to 12 FDA-approved drugs, including monoclonal antibodies (rituximab, obinutuzumab), antibody-drug conjugates (polatuzumab), bispecific antibodies (epcoritamab, glofitamab), targeted small-molecule inhibitors (venetoclax, everolimus, zanubrutinib), and cytotoxic chemotherapies (gemcitabine, oxaliplatin, cyclophosphamide, doxorubicin). This study demonstrates the feasibility of Optim.AI™ 2.0, an enhanced co-culture-based platform which provides a physiologically relevant and scalable approach to functionally evaluate immunotherapy drug sets. With further validation, Optim.AI™ 2.0 holds strong potential to support clinical decision-making and expand the use of immunotherapies in DLBCL."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Sarcoma • Solid Tumor

Cardiovascular safety profile of CD20 × CD3 bispecific antibodies compared to immune-checkpoint inhibitors: A faers analysis, 2014–2025 (ASH 2025) - "Background: Bispecific T-cell engagers (BTEs) have evolved from CD19 × CD3 constructs such as blinatumomab to newer CD20 × CD3 agents, including mosunetuzumab, glofitamab, and epcoritamab. CD20 × CD3 bispecifics are associated with a distinct arrythmia signal, more frequent and earlier than that observed with ICIs. However, overall arrhythmia reporting has declined over time, likely reflecting improved mitigation strategies such as step-up dosing and early monitoring. Nonetheless, the absolute incidence (2.8%) exceeds that seen with ICIs, supporting baseline ECG and rhythm surveillance during CD20 BTE initiation."

Checkpoint inhibition • Clinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders • Inflammation • Oncology • Venous Thromboembolism • CD20 • ROR1

Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study (ASH 2025) - P | "Pretreatment included obinutuzumab 1000mg (Cycle 1 Day 1), followed by glofitamab step-up dosing (2.5mg C1D8, 10mg C1D15, 30mg from C2D1). This real-world study demonstrates favorable efficacy and manageable safety of glofitamab-based salvage therapy in R/R aggressive B-cell lymphomas. Combination therapy significantly improved outcomes, with no regimen-dependent differences observed. CRS and infections require vigilant monitoring, but the regimen offers a promising therapeutic option for this refractory population."

Clinical • IO biomarker • Observational data • Real-world • Real-world evidence • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Infectious Disease • Lymphoma • Marginal Zone Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Richter's Syndrome • BCL2 • CD20 • MYC

Efficacy, safety, and T-cell population dynamics of glofitamab monotherapy in relapsed/refractory B-cell lymphoma (ASH 2025) - "Patients and methods All patients with R/R BCL received a single dose of obinutuzumab pretreatment (1,000 mg) 7 days before the first cycle of glofitamab. After two cycles therapy, the incidence of CRS and the level of IL-6 decreased significantly. It is very interesting that T-cell exhaustion in the early stage of treatment might be associated with better therapeutic effects."

Clinical • Monotherapy • B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • CD4 • CD8 • IL6

Glofitamab effectively bridging CD19-specific CAR T- cell therapy while maintaining safety in patients with refractory DLBCL (ASH 2025) - "The median progression-free survival (PFS) was 6.5 months (95%CI,5.25-7.75), whereas the median overall survival was not achieved for patients. In summary, glofitamab birding CART therapy demonstrates promising efficacy and a manageable safety profile in refractory DLBCL in a real-world scenario."

CAR T-Cell Therapy • Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • TP53

Real-world descriptive analysis of the use of bispecific t cell engagers (BiTEs) in the treatment of hematological malignancies in Qatar: A state-wide retrospective cohort study (ASH 2025) - "Nevertheless, in r/r multiple myeloma (MM) elranatamab and teclistamab have been used to target BCMA. Another BiTE targeting CD20 used in r/r follicular lymphoma (FL) such as mosunetuzumab, and glofitamab in r/r diffuse large B cell lymphoma (DLBCL), while epcoritamab has been approved in both indications (Shouse G., 2025)...Method This is a descriptive retrospective cohort study, including all adult hematological patients who were treated with BiTEs: epcoritamab, glofitamab, blinatumomab, and teclistamab...Despite the small sample size and the study design, our findings nearly comply with primary literature that BiTEs serve as a promising therapeutic alternative for patients with relapsed or refractory disease, particularly those who have exhausted other modalities. However, the high incidence of reported adverse drug reactions (ADRs), including severe toxicities such as CRS and ICANS, highlights the need for robust and careful strategies for safety and tolerability..."

Real-world • Real-world evidence • Retrospective data • Acute Lymphocytic Leukemia • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

Analysis of factors associated with clinical response in glofitamab's treatment of relapsed or refractory (R/R) large B-cell lymphoma (ASH 2025) - "Multivariate analysis showed patients with bulky disease were independently associated with inferior outcomes. This conclusion requires confirmation through studies with larger sample sizes."

Clinical • IO biomarker • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • CD4 • CD8 • CXCL8 • IL6 • TNFA

Favorable Outcomes of Bridging Glofitamab Prior to anti-CD19 CAR-T cell Therapy in patients with non-Hodgkin lymphoma (ASH 2025) - " Pts with R/R NHL who underwent leukapheresis received pre-treatment with obinutuzumab prior to the first dose of glofitamab. Based on disease progression status, pts received glofitamab monotherapy or glofitamab combined with gemcitabine + oxaliplatin/ BTK inhibitor/ methotrexate regimens prior to CAR-T infusion... Glofitamab bridging therapy prior to CAR-T demonstrated promising efficacy in pts with high-risk NHL, without significant safety concerns or detrimental impact on CAR-T cell kinetics. This study provides preliminary evidence for redefining therapeutic paradigms in non-Hodgkin lymphoma, particularly PCNSL, supporting further investigation through expanded validation cohorts and longitudinal outcomes assessment."

CAR T-Cell Therapy • Clinical • IO biomarker • B Cell Lymphoma • Bone Marrow Transplantation • Burkitt Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • TP53

Safety and efficacy of glofitamab in combination with lenalidomide in relapsed or refractory central nervous system lymphoma: Real-world data (ASH 2025) - "Pretreatment with obinutuzumab (1000 mg) was administered intravenously 7 days before the first dose of glofitamab. Glofitamab was then administered intravenously by step-up dosing during cycle 1 (day 8: 2.5 mg; day 15: 10 mg), followed by fixed-dose glofitamab 30 mg on day 1 of cycles 2~12 To mitigate the risk of cytokine release syndrome (CRS), patients received premedication (dexamethasone 20mg intravenously, acetaminophen 1000mg orally, isopropanazine 25mg intramuscularly) 1 hour before glofitamab therapy... The cohort comprised one male and three females, with a mean age of 58 years (range: 51~69). Median time to relapse after last treatment was 5 months (range: 3~8). Relapse symptoms included neurological symptoms (such as headache, lethargy, limb weakness, gait disturbance, slurred speech, visual deficits, etc.) and systemic symptoms (such as nausea, anorexia, fatigue, etc.) After two cycles of treatment, all patients achieved rapid remission (two complete..."

Clinical • Combination therapy • Real-world • Real-world evidence • Anorexia • B Cell Lymphoma • Brain Cancer • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Solid Tumor • CD20

Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL (ASH 2025) - "Short-course CD20×CD3 BsAb therapy with glofitamab as a bridging and cytoreductive strategy before CAR-T infusion may reduce tumor burden and improve treatment feasibility in B-NHL. Further prospective validation is warranted."

B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • CD20

Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma (ASH 2025) - "Introduction: Glofitamab, a bispecific antibody targeting CD20 and CD3, is approved for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) following at least one prior line of therapy, either as monotherapy or in combination with gemcitabine and oxaliplatin (GemOx)...Specifically, 6 patients (17.1%) had a history of bendamustine exposure, and 4 patients (11.4%) had undergone both autologous stem cell transplantation and chimeric antigen receptor T-cell therapy...Among them, the regimens included glofitamab monotherapy (28, 80.0%), glofitamab combination with bruton tyrosine kinase inhibitors (3, 8.6%), GemOx (2, 5.7%), polatuzumab vedotin (1, 2.9%) or dose-reduced ifosfamide, carboplatin and etoposide (1, 2.9%)... Our findings characterize disease features of heavily treated r/r aggressive B-cell lymphoma and real-world outcomes with glofitamab-based salvage. Even in the subgroups with adverse prognosis factors, glofitamab-based regimens still demonstrated..."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • CD4 • TP53

Glofitamab based combined therapy as bridging therapy before stem cell transplants and CAR-T therapy in large B-cell lymphoma. (ASH 2025) - "Glofitamab-based combination therapy has a high response rate as a bridge to stem cell transplantation and car-t therapy for large B-cell lymphoma. The safety was manageable and the treatment discontinuation rate was low. Updated data will be provided."

IO biomarker • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Transplantation

Glofitamab-based combinatorial therapy demonstrates high efficacy in primary refractory and early relapsed DLBCL: Real-world evidence of durable responses and immune modulation in high-risk subgroups (ASH 2025) - "Tocilizumab was administered in 8.3% (1/12)...Notably, this activation persisted without exhaustion through 6 cycles, including in CAR-T–pretreated ( n =2) and bendamustine-exposed ( n =2) subgroups, suggesting sustained modulation of the tumor immune microenvironment... Glofitamab exhibits clinically significant activity in primary refractory and early relapsed DLBCL through potent T/NK-cell engagement, inducing durable responses across high-risk subtypes. Real-world data support combinability with Polatuzumab Vedotin, PD-1 immune checkpoint inhibitor, GemOx, BTKi, or radiotherapy, warranting proactive toxicity monitoring. These findings establish glofitamab as a transformative backbone therapy for resistant DLBCL, addressing critical unmet needs via its unique immune-redirecting mechanism."

Clinical • HEOR • IO biomarker • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Immune Modulation • Immunology • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Respiratory Diseases • CD20 • CD4 • CD5 • CD8 • TP53

Real-world efficacy, safety, and predictive factors for response to glofitamab in Chinese patients with relapsed/refractory aggressive B-cell lymphoma: A multicenter study (ASH 2025) - "In this multicenter, real-world study of Chinese patients with R/R aggressive B-cell lymphoma, glofitamab-based therapy demonstrated substantial efficacy, achieving high response rates and promising survival outcomes. At the same time, the safety profile was predictable and manageable, with a low incidence of severe CRS. Our findings suggest that glofitamab is a valuable therapeutic option for this challenging patient population."

Biomarker • Clinical • Real-world • Real-world effectiveness • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma

A prospective, multicenter, real-world study of glofitamab in Chinese patients with relapsed or refractory large B-cell lymphoma (ASH 2025) - P | "In real-world settings, glofitamab, as monotherapy or combination therapy, demonstrated rapid responses and high remission rates in high-risk, heavily pretreated R/R LBCL patients, with manageable safety. Future studies will expand sample size and follow-up to confirm these findings."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Primary Mediastinal Large B-Cell Lymphoma

Therapeutic outcomes of glofitamab-based regimens in Chinese patients with Relapsed/Refractory B-cell lymphoma: A single-center retrospective real-world study (ASH 2025) - "Treatment regimens consisted of glofitamab monotherapy (n=10), glofitamab plus chemotherapy (n=8), and glofitamab plus polatuzumab vedotin (n=2). Glofitamab-based therapy shows superior efficacy and a manageable safety profile in Chinese R/R B-cell lymphoma patients, potentially establishing it as a preferred treatment option for this population."

IO biomarker • Real-world • Real-world evidence • Retrospective data • B Cell Lymphoma • Burkitt Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Pneumonia • Primary Central Nervous System Lymphoma • Respiratory Diseases • TP53

The research on the immune microenvironment of patients with relapse or refractory diffuse large b faced drug resistance to CD20/CD3 bispecific antibodies (ASH 2025) - "Approximately 40% of patients still experience refractory or relapsed conditions after receiving the standard RCHOP regimen.In recent years, immunotherapy has completely transformed the treatment landscape for patients with R/R DLBCL. In this study, we explored the immune microenvironment of drug-resistant R/R DLBCL patients on CD20/CD3 BsAbs. It's confirmed the T cells driven effect of CD20/CD3 BsAbs. And after that, we described the dynamic T cells profiles, indicated the T cells exhaustion may play the key role in CD20/CD3 BsAbs drug resistance."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • CD20 • CD4 • CD8 • IFNG • IL23A • IL4 • IL6

Pooled analysis of early-Phase trials highlights robust activity of CD3-CD20 T-cell engagers in follicular lymphoma (ASH 2025) - "It was not feasible to compare monotherapy withcombination therapy trials due to limitations in the reported risk categories of patients enrolled.R/R FL: In the relapsed setting, Epcoritamab was included in 3 trials (one of which was incombination with lenalidomide and rituximab (R2)), Mosunetuzumab in 2, Glofitamab in 1, andOdronextamab in 1. This pooled analysis confirms that CD3-CD20 TCE therapies achieve high overall andcomplete response rates in FL. This is particularly seen in the frontline setting. Responses in R/R werealso clinically meaningful and durable, especially given that most trials enrolled patients with at least 2 ormore previous lines of therapy."

Retrospective data • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • CD20